July 24, 2017 |
Pharma Archives

January 10, 2017 | Pharma

Portugal — New research into Parkinson’s disease suggests that people with the disease may achieve better and more reliable motor control by taking opicapone, an experimental drug, alongside the standard levodopa. A study of several hundred Parkinson’s patients found that the drug boosts levodopa’s ability to control the motor difficulties associated with Parksinson’s, including tremors, stiffness and slowed movement, said Dr. Patricio Soares-da-Silva, the study&rs [...]
Read More...

December 9, 2016 | Pharma

London, UK — A study preformed by researchers from Imperial College in London has concluded that psilocybin – the active compound found in psychedelic mushrooms – may be an effective therapeutic treatment for patients with unipolar treatment-resistant depression. In the study, 12 patients, who had found no relief from depressive symptoms after two separate anti-depressant regiments, were administered two oral doses of psilocybin – one small, one large – a week apar [...]
Read More...

October 25, 2016 | Pharma

Sioux Falls, SD – Sanford Health has opened another clinical trial exploring the power of the body’s immune system to fight cancer. The immunotherapy trial is focusing on colorectal cancer and involves an investigational drug Sanford is already studying as a potential therapy for other types of cancer. The drug, pembrolizumab, blocks a protein in the body that allows cancerous cells to thrive. This inhibition of the protein allows the body’s immune system to recognize and [...]
Read More...

May 13, 2016 | Pharma

Warrenville, IL – Time is of the essence, and saving time for nurses in med preparations at skilled-nursing communities is a reachable operational efficiency according to a unique new study by researchers at the University of North Texas in Denton, Texas. The study showed savings gained by using strip packaging for oral medications over bingo card packaging can total more than 1,200 hours of nurse time per site or nearly $40,000 annually. For an organization of 20 communities, the savings [...]
Read More...

February 1, 2016 | Pharma

New York, NY - The use of antiretroviral therapy (ART) taken as pre-exposure prophylaxis (PrEP) could lead to a marked decline in HIV incidence—the annual rate of infection—among men who have sex with men (MSM) in the UK by the end of this decade, new modelling research published in The Lancet HIV journal suggests. The research shows that offering PrEP alongside regular HIV testing and early treatment to just a quarter of MSM at high risk of contracting HIV could prevent around 7400 [...]
Read More...

November 19, 2015 | Pharma

Los Angeles, CA -- Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is painful and risky and must be repeated every few weeks. UCLA researchers have found that a drug that inhibits a receptor called the Colony-Stimulating-Factor-1 Receptor, or CSF1R, reduces ascites with minimal side effects. This inhibition therapy targe [...]
Read More...

August 21, 2015 | Pharma

San Francisco, CA - A class of drugs widely used to treat dementia -- called cholinesterase inhibitors -- could cause harmful weight loss in some patients, a new study suggests. These medications include Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine). "Our study provides evidence in a large, real-world population that cholinesterase inhibitors may contribute to clinically significant weight loss in a substantial proportion of older adults with dementia," study lead autho [...]
Read More...

July 22, 2015 | Pharma

Baltimore, MD - Research with human tissue and cells suggests that genetic variations, in addition to failure to comply with treatment regimens, may account for some failures of an anti-HIV drug to treat and prevent HIV infection. In a report described online in the journal EBioMedicine, investigators at Johns Hopkins found that tenofovir, marketed as Viread, is processed differently according to cell location, so that if the drug is eventually marketed as a topical gel, it could work di [...]
Read More...

June 24, 2015 | Pharma

Albuquerque, NM - Summer inspires many people to think about their vacation plans; it makes Montaser Shaheen, MD, think about melanoma. Shaheen is a medical oncologist at the University of New Mexico Cancer Center. He and colleagues from around the country recently published a paper in the New England Journal of Medicine about a promising new treatment for melanoma. Shaheen ran the UNM Cancer Center's portion of the clinical trial from which the paper's data was collected. He hope [...]
Read More...

May 18, 2015 | Pharma

New York, NY - More than a half-million U.S. patients had medication costs in excess of $50,000 in 2014, an increase of 63 percent from the prior year, as doctors prescribed more expensive specialty drugs for diseases such as cancer and hepatitis C, according to an Express Scripts report released on Wednesday. Of the estimated 575,000 Americans who used at least $50,000 in prescription medicines last year, about 139,000 used at least $100,000 worth of medication, nearly triple the 47,000 who hi [...]
Read More...

December 3, 2014 | Pharma

Riverside, CA – Given the debilitating effects of Multiple sclerosis (MS), an aggressive search is on among scientists to find a cure. Currently available therapies are only partially effective, however, in preventing the onset of permanent disability in MS patients. What would be immensely helpful is a drug that could minimize the degeneration of axons, thus reducing the rate and degree of MS progression. Better still would be if this drug could stimulate “remyelination,” [...]
Read More...

November 18, 2014 | Pharma

Bethesda, MD - Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health (NIH). One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. The results of the HALT-PKD Clinical Trials [...]
Read More...

November 6, 2014 | Pharma

Denver, CO - A University of Colorado Cancer Center study published in this month’s Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body’s immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens. “Knowing this [...]
Read More...

September 10, 2014 | Pharma

Los Angeles, CA - The U.S. Food and Drug Administration recently approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated. The drug, Keytruda, was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the patients in the early testing showed significant long-lasting responses, the study was continued and the FDA granted the drug “breakthrough therapy&rd [...]
Read More...

August 25, 2014 | Pharma

Baltimore, MD - Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects. More positively, the researchers say, their work provides the basis for a test that drug developers ca [...]
Read More...

August 13, 2014 | Pharma

La Jolla, CA - It’s a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be “undruggable.” The researchers found that a credit card-like molecule they developed somehow moves in and disrupts the critical interactions between MYC and its binding partner. The research, published t [...]
Read More...

August 4, 2014 | Pharma

Chicago, IL – Statin therapy may help to improve wound healing in patients following cardiac surgery and reduce overall recovery time, especially in patients who are prone to healing complications, according to a review article in the August 2014 issue of The Annals of Thoracic Surgery. “Statins have become one of the most widely prescribed medications in the world. While they are typically used to manage high cholesterol levels, a number of researchers have been investigating [...]
Read More...

July 8, 2014 | Pharma

Liverpool, UK - A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes - such as a reduced rate of repeat heart attacks - compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries. Bivalirudin is around 400 times more expensive than heparin. The results of the HEAT-PPC [...]
Read More...

June 25, 2014 | Pharma

Drug avoids negative impact on liver function, HDL levels Chicago, IL — Muscle wasting that occurs as a result of cancer negatively impacts the well-being and recovery prospects of millions of patients, particularly the rapidly-growing elderly population. Selective androgen receptor modulators drugs (SARMs) offer hope for these patients, and a new SARM for transdermal administration is promising excellent efficacy without harming liver function and HDL levels. Results and conclusions [...]
Read More...

June 5, 2014 | Pharma

Boston, MA - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago. This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed by a randomized phase 2 trial sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. The tria [...]
Read More...

May 28, 2014 | Pharma

Atlanta, GA - The U.S. Food and Drug Administration today approved Dalvance (dalbavancin), a new antibacterial drug used to treat adults with skin infections. Dalvance is intended to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria like Staphylococcus aureus(including methicillin-susceptible and methicillin-resistant strains) andStreptococcus pyogenes. The treatment is administered intravenously. Dalvance is the first drug designated [...]
Read More...

May 12, 2014 | Pharma

Little Rock, AR - The first-ever treatment for multicentric Castleman’s disease - a rare blood disorder - was approved recently by the Food and Drug Administration after drug trials headed by a researcher at the University of Arkansas for Medical Sciences (UAMS).  Frits van Rhee, M.D., Ph.D., the nation’s leading expert in Castleman’s disease, led the years-long study of siltuximab in conjunction with Horsham, Pa.-based Janssen Biotech Inc. The drug was approv [...]
Read More...

March 13, 2014 | Pharma

Boston, MA - A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, and genomic profiling of his tumor revealed two alterations that may have led to this exceptional response. This information can help identify cancer patients who may respond to everolimus, according to the report published in Cancer Discovery, a journ [...]
Read More...

March 5, 2014 | Pharma

Boston, MA - A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check – for more than two years, in some cases – in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions. The study, published online March 3rd, by the Journal of Clinical Oncology, provides the longest-term look so far at how [...]
Read More...

January 29, 2014 | Pharma

Baltimore, MD - Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself. The Johns Hopkins scientists who conducted the trial said the finding is significant because measuring immune system responses directly in the lesions may be a more accurate way to evaluate so-called “therapeutic” vaccines than by the conventional means of blood analysis. [...]
Read More...

January 16, 2014 | Pharma

Hints to Future Injection-Free Therapies Baltimore, MD - Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere. In a study reported today in the New England Journal of Medicine, researchers say combination treatments involving a pair of experimental, oral antiviral drugs, daclatasvir and sofosbuvir, were safe and highly eff [...]
Read More...

January 7, 2014 | Pharma

Portland, OR - Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease. The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal. The discovery [...]
Read More...

December 18, 2013 | Pharma

Chicago, IL  – A new guideline for the management of high blood pressure, developed by an expert panel and containing nine recommendations and a treatment algorithm (flow chart) to help doctors treat patients with hypertension, was published online by JAMA.  Hypertension is the most common condition seen in primary care and leads to heart attack, stroke, kidney failure, and death if not detected early and treated appropriately. “Patients want to be assured that blood press [...]
Read More...

December 4, 2013 | Pharma

Ann Arbor, MI — A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 22 percent of patients developing graft-vs.-host disease compared to 42 percent of [...]
Read More...

November 18, 2013 | Pharma

Bethesda, MD - A commonly used stenting procedure to treat plaque build-up in the renal artery appears to offer no significant improvement when added to medication-based therapy, according to results from a National Institutes of Health-funded study. The narrowing and hardening of one or both renal arteries, known as renal artery stenosis, occurs in 1 to 5 percent of people who have high blood pressure, or hypertension. The findings were presented at the American Heart Association (AHA) 2013 Sc [...]
Read More...

November 4, 2013 | Pharma

Bethesda, MD -The generic anticonvulsant medication gabapentin shows promise as an effective treatment for alcohol dependence, based on the results of a 150-patient clinical trial of the medication. Conducted by scientists supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, the study found that alcohol dependent patients using gabapentin were more likely to stop drinking or refrain from heavy drinking than those taking placebo. [...]
Read More...

September 24, 2013 | Pharma

Newark, NJ -  The topical anti-fungal drug Ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells’ powerhouse, the mitochondria — according to a study by researchers at Rutgers New Jersey Medical School. And unlike current anti-HIV drugs, Ciclopirox completely eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped. The study has been published in the journal PLOS One. The treatment of patients with HIV has been re [...]
Read More...

September 16, 2013 | Pharma

Chapel Hill, NC – Researchers at the University of North Carolina School of Medicine have published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease. The research appeared in the Journal of Clinical Investigation. “We believe we may have found an optimized treat [...]
Read More...

September 4, 2013 | Pharma

Memphis, TN - A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children’s Research Hospital. The report appears in the advance online edition of the journal Pediatrics. The study is the largest ever focusing on the economic impact of the drug hydroxyurea in children with the inherited blood disord [...]
Read More...

August 19, 2013 | Pharma

New York, NY - Patients with an aggressive lymphoma that often relapses and kills within two years experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially-available drug that made chemotherapy more effective.  Researchers from Weill Cornell Medical College and NewYork-Presbyterian Hospital, who led the study published in Cancer Discovery, say their strategy has the potential to change the standard of care for patients with diffuse la [...]
Read More...

August 13, 2013 | Pharma

Columbus, OH - Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health. The study, led by a team in The Research Institute at Nationwide Children’s Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allow [...]
Read More...

August 6, 2013 | Pharma

Sacramento, CA — UC Davis researchers have identified how and where in the genome a cancer chemotherapy agent acts on and ‘un-silences’ the epigenetically silenced gene that causes Angelman syndrome. The agent, Topotecan, is a topoisomerase inhibitor, part of a class of drugs that in earlier research has been found to un-silence the Angelman gene, suggesting that it might be therapeutic for the condition, which affects approximately 1 in 25,000, or approximately 150,000 people [...]
Read More...

July 31, 2013 | Pharma

Bethesda, MD - Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when started at middle age, reports an international team of scientists led by researchers at the National Institute on Aging (NIA), part of the National Institute of Health. The study, which tested two doses of the drug in the male mice, found the higher dose to be toxic in the animals. Scientists emphasized that considerably more research is needed before the implicat [...]
Read More...

July 22, 2013 | Pharma

Atlanta, GA - Two new antibiotic regimens using existing drugs - injectable gentamicin in combination with oral azithromycin and oral gemifloxacin in combination with oral azithromycin - successfully treated gonorrhea infections in a clinical trial. The trial was conducted by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). The study was conducted to identify new treatment options in the face of growing antibiotic resistance. The findings were pr [...]
Read More...

July 19, 2013 | Pharma

Columbus, OH - Celebrex (Celecoxib), a drug currently marketed for its anti-inflammatory properties, may have anti-tumor and cancer prevention effects, particularly because it blocks STAT3 signaling, suggests new research.Celecoxib is a COX-2 inhibitor that has recently been gaining credit for its anti-tumor effects as well.  Investigators at Nationwide Children’s and The Ohio State University suspect that its anti-tumor powers are tied, in part, to the drug’s ability to bind to [...]
Read More...

June 21, 2013 | Pharma

INDIANAPOLIS – Franciscan St. Francis Health Cancer Center is using a new drug to treat men with advanced prostate cancer. It’s called Xofigo® (radium Ra 223 dichloride), a radiopharmaceutical used in patients with late-stage, metastatic disease that has spread to the bones. It recently was approved for use by the U.S. Food and Drug Administration. As prostate cancer progresses to advanced stages it may become castration-resistant, which has become resistant to medical or [...]
Read More...

May 31, 2013 | Pharma

Discovery could help in drug development to attack Alzheimer's, Parkinson's and other neurological disorders   Portland, OR ­– For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditi [...]
Read More...

May 16, 2013 | Pharma

Combination of denosumab and teriparatide produces greatest reported increase in bone density   BOSTON, MA - A combination of two FDA-approved osteoporosis drugs with different mechanisms of action was found to increase bone density better than treatment with either drug alone in a small clinical trial. As reported in The Lancet, Massachusetts General Hospital (MGH) investigators found that treatment combining denosumab (Prolia) and teriparatide (Forteo) was superior to single-agent treat [...]
Read More...

April 16, 2013 | Pharma

Houston, TX – A patient suffering from advanced heart failure is the first in Texas to be treated with the new investigational drug MYDICAR® in a clinical trial at St. Luke’s Episcopal Hospital, home of the Texas Heart® Institute. The procedure, involving a catheter-based infusion into the arteries of the heart with an investigational new drug called MYDICAR, was performed in mid-March by Andrew Civitello, MD and Leo Simpson, MD.  Dr. Civitello is an intervent [...]
Read More...

March 25, 2013 | Pharma

New York, NY - Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells. Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest t [...]
Read More...

February 25, 2013 | Pharma

Baltimore, MD - In an update to previous research, Johns Hopkins neurologists say minimally invasive delivery of the drug tPA directly into potentially lethal blood clots in the brain helped more patients function independently a year after suffering an intracerebral hemorrhage (ICH), a deadly and debilitating form of stroke. Rates of functional recovery with the active tPA treatment far surpassed those achieved with standard “supportive” therapy that essentially gives clots a chance [...]
Read More...

January 31, 2013 | Pharma

Los Angeles, CA - A combination therapy using an experimental new drug shows significant promise for women with a common type of breast cancer in which estrogen causes their tumors to grow, researchers with the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center report. The treatment, which incorporates the standard anti-estrogen therapy letrozole and the experimental drug PD 0332991, developed by pharmaceutical company Pfizer Inc., was found to increase pr [...]
Read More...